



ABN 53 075 582 740

ASX ANNOUNCEMENT
20 March 2017

**Bionomics to Host KOL Meeting Focused on PTSD and Anxiety
on March 23, 2017 in New York**

Bionomics Limited (ASX:BNO, OTCQX:BNOEF), a biopharmaceutical company focused on the discovery and development of innovative therapeutics for the treatment of diseases of the central nervous system (CNS) and cancer, announced today that it will host a Key Opinion Leader (KOL) breakfast focused on the growing importance of the alpha-7 nicotinic acetylcholine receptor in a variety of CNS disorders, including generalized anxiety disorder (GAD) and post-traumatic stress disorder (PTSD), on Thursday, March 23, 2017 from 8:30 a.m. to 10:30 a.m. ET in New York.

The meeting will feature keynote presentations from:

- **Professor Allan H Young, MB ChB, MPhil, PhD, FRCPsych, FRCPC, FRSB.**, Director for the Centre for Affective Disorders in the Department of Psychological Medicine, Institute of Psychiatry, Psychology and Neuroscience at King's College London
- **Professor Marina Picciotto, Ph.D.**, Charles B. G. Murphy Professor and Deputy Chair for Basic Science Research, Department of Psychiatry, Professor of Neuroscience and Pharmacology, Yale University
- **Adam Perkins, Ph.D.**, Lecturer in the Neurobiology of Personality for the Centre for Affective Disorders, in the Department of Psychological Medicine, Institute of Psychiatry, Psychology & Neuroscience at King's College London

Additionally, executives from Bionomics will provide an overview of the Company's CNS pipeline, data from its recent Phase 2 study in GAD and its ongoing Phase 2 study of BNC210 in PTSD.

A live audio webcast can be accessed on the Bionomics website, www.bionomics.com.au. An archived replay of the webcast will be available for 30 days after the live event concludes.

FOR FURTHER INFORMATION PLEASE CONTACT:

Australia

Monsoon Communications
Rudi Michelson
+613 9620 3333
rudim@monsoon.com.au

US

Stern IR, Inc.
Beth Del Giacco
+1 212 362 1200
beth@sternir.com

About Bionomics Limited

Bionomics (ASX: BNO) is a global, clinical stage biopharmaceutical company leveraging its proprietary platform technologies to discover and develop a deep pipeline of best in class, novel drug candidates focused on the treatment of

serious central nervous system disorders and on the treatment of cancer. Bionomics' lead drug candidate BNC210, currently in Phase 2 for the treatment of generalized anxiety disorder and for post-traumatic stress disorder, is a novel, proprietary negative allosteric modulator of the alpha-7 ($\alpha 7$) nicotinic acetylcholine receptor. The Company is also developing BNC101, its lead humanized monoclonal antibody targeting a key receptor on cancer stem cells that is overexpressed in metastatic colorectal cancer, metastatic pancreatic cancer and many other solid tumours; BNC101 entered clinical trials in the first quarter of 2016. Bionomics has strategic partnerships with Merck & Co., Inc (known as MSD outside the United States and Canada) in pain and cognition.

www.bionomics.com.au

Factors Affecting Future Performance

This announcement contains "forward-looking" statements within the meaning of the United States' Private Securities Litigation Reform Act of 1995. Any statements contained in this announcement that relate to prospective events or developments, including, without limitation, statements made regarding Bionomics' drug candidates (including BNC210 and BNC101), its licensing agreements with Merck & Co. and any milestone or royalty payments thereunder, drug discovery programs, ongoing and future clinical trials, and timing of the receipt of clinical data for our drug candidates are deemed to be forward-looking statements. Words such as "believes," "anticipates," "plans," "expects," "projects," "forecasts," "will" and similar expressions are intended to identify forward-looking statements.

There are a number of important factors that could cause actual results or events to differ materially from those indicated by these forward-looking statements, including unexpected safety or efficacy data, unexpected side effects observed in clinical trials, risks related to our available funds or existing funding arrangements, our failure to introduce new drug candidates or platform technologies or obtain regulatory approvals in a timely manner or at all, regulatory changes, inability to protect our intellectual property, risks related to our international operations, our inability to integrate acquired businesses and technologies into our existing business and to our competitive advantage, as well as other factors. Results of studies performed on our drug candidates and competitors' drugs and drug candidates may vary from those reported when tested in different settings.